Lyndra Therapeutics and Thermo Fisher Partner for Long-Acting Oral Therapies

Lyndra Therapeutics, a biopharmaceutical company in the clinical stage, has formed a strategic partnership with Thermo Fisher Scientific Inc., wherein Thermo Fisher will offer global clinical research and commercial manufacturing services to...

Alembic Pharma Secures USFDA Nod for Generic Brexpiprazole Tablets

Alembic Pharmaceuticals Ltd announced that it has secured final approval from the US health regulator for its generic variant of Brexpiprazole tablets, which are used in treating major depressive disorder. The company announced that the US Food &...

AstraZeneca, Daiichi Sankyo's Dato-DXd Earns Priority Review for EGFR NSCLC

The Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) from AstraZeneca and Daiichi Sankyo has been accepted and awarded Priority Review status in the US for treating adult patients with locally advanced or metastatic...

Rappta Therapeutics and SpringWorks Partner on Molecular Glue Targeting PP2A

Rappta Therapeutics (Rappta), focused to creating first-in-class anti-cancer therapies that activate protein phosphatase 2A (PP2A), has announced a global exclusive licensing agreement with SpringWorks Therapeutics (SpringWorks) for RPT04402...

Odisha Set to Boost Economy with New Pharmaceutical Manufacturing Hub

Odisha government is preparing to establish a pharmaceutical manufacturing hub, which has the potential to significantly impact job creation and economic development in the state. In preparation for the major investment summit Utkarsh Odisha: Make...

Hikma Partners with Emergent To commercialize KLOXXADO in the US and Canada

Hikma Pharmaceuticals PLC, the global pharmaceutical company, has formed an exclusive commercial alliance with Emergent BioSolutions for marketing KLOXXADO naloxone HCl nasal spray 8 mg in the U.S. and Canada. KLOXXADO received approval from the...

Roche Secures US FDA Approval for its Ultra-Sensitive ISH test

Roche announced that it has obtained 510(k) approval from the United States Food and Drug Administration (FDA) for its ultra-sensitive in-situ hybridisation (ISH) assay, the VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail. The assessment...

ProMIS Neurosciences Unveils Phase 1b Trial for Alzheimer's Candidate PMN310

ProMIS Neurosciences Inc., a biotechnology company at the clinical stage aimed at creating precise therapies for neurodegenerative diseases, announced the start of its phase 1b clinical trial (PRECISE-AD) assessing its primary therapeutic...

Crinetics Pharma Reports Positive Phase 2 study for Atumelnant in CAH

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical firm, announced encouraging topline findings from an open-label, phase 2 study on congenital adrenal hyperplasia (CAH) using investigational atumelnant, a new, once-daily oral...

Cycle Pharma Acquires Banner Life Sciences

Cycle Pharmaceuticals, Inc. (Cycle) has announced the successful acquisition of Banner Life Sciences, LLC (Banner), which encompasses its BAFIERTAM® (monomethyl fumarate) product for treating relapsing forms of multiple sclerosis (MS) in adults...

© 2025 India Pharma Outlook. All Rights Reserved.